Treatment Information

Back

Rectal Cancer treatment details. Biologic therapy.

Princess Margaret Hospital, Toronto, Ontario, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:3City/State/Province:Toronto, Ontario
Treatments:Biologic therapyHospital:Princess Margaret Hospital
Drugs:Journal:Link
Date:Aug 2005

Description:

Patients: This Phase II study involves 19 patients with metastatic colorectal cancer (17 colon, 2 rectal). Nine patients were men, and ten were women. The median age was 62. All patients had previously received chemotherapy. Metastatic sites included liver, lung, and lymph nodes.

Treatment: The treatment consisted of one chemotherapeutic drug: bortezomib.

Toxicities: Thirteen patients died, but the authors do not say whether these deaths were caused by the treatment. No grade 4 toxicities were reported. Grade 3 toxicities included lymphopenia, abdominal pain, vomiting, and sensory neuropathy.

Results: There were no objective responses. The overall median survival was 28.3 weeks (7.1 months) for all patients. The authors did not observe an effective antitumor response by bortezomib and, as a result, did not recommend further study of this drug as a single anti-cancer agent in treating metastatic colorectal cancer.

Correspondence: Amit Oza, MD




Back